Swiss pharmaceutical giant novartis ag CEO Vas Narasimhan said on Wednesday that the company does not intend to join the "craze" for weight loss drugs, but prefers to focus on areas where it can establish a "unique position". Vas Narasimhan stated in a media interview that the company is researching treatment methods for the secondary effects of weight loss drugs, but does not plan to directly compete with leading obesity drug manufacturers novo-nordisk a/s and eli lilly and co. The stimulating effect of a drug refers to the non-direct therapeutic effects produced by drug therapy. In pharmacology, secondary effects usually refer to indirect or additional effects of a drug on the target disease or symptoms. These effects may be caused by other biological actions of the drug in the body, or side effects associated with the drug's main therapeutic mechanism. Vas Narasimhan said: "I think for novartis, it is not the right move to simply follow this frenzy." (Global Market Report)